Inventor · disambiguated record

James D. Mcininch

Also filed as: MCININCH JAMES · MCININCH JAMES D

26 granted patents·61 pending applications·312 citations·filing 1999–2025

94Inventor score

Technology areasC12N A61K C07K C12Y G16B

Files withALNYLAM PHARMACEUTICALS INC75 MONSANTO TECHNOLOGY LLC6 BOUKHAROV ANDREY A3 BOUKHAROV ANDREY1 LA ROSA THOMAS1

Top patents by PatentIndex Score

87 records

0198US7868149B2Plant genome sequence and uses thereofMONSANTO TECHNOLOGY LLC·Filed 2006·Granted Jan 11, 2011·159 cites·20 claims
0297US7365185B2Genomic plant sequences and uses thereofMONSANTO TECHNOLOGY LLC·Filed 2001·Granted Apr 29, 2008·102 cites·15 claims
0394US11326166B1Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted May 10, 2022·3 cites·29 claims
0494US11149276B2Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Oct 19, 2021·4 cites·30 claims
0594US7790958B2Genomic plant sequences and uses thereofMONSANTO TECHNOLOGY LLC·Filed 2006·Granted Sep 7, 2010·28 cites·30 claims
0693US11926832B2Ketohexokinase (KHK) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Mar 12, 2024·4 cites·30 claims
0793US11208660B1Coronavirus iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Dec 28, 2021·3 cites·30 claims
0892US11959081B2Transthyretin (TTR) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 16, 2024·1 cites·30 claims
0991US11965166B2Complement factor B (CFB) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Apr 23, 2024·1 cites·30 claims
1090US11993774B2Huntingtin (HTT) iRNA agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted May 28, 2024·1 cites·30 claims
1184US11162103B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Nov 2, 2021·1 cites·23 claims
1283US11866710B2Transmembrane protease, serine 6 (TMPRSS6) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Jan 9, 2024·1 cites·46 claims
1382US12331297B2Coagulation factor V (F5) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Jun 17, 2025·0 cites·28 claims
1482US12258565B2Complement component C3 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Mar 25, 2025·0 cites·28 claims
1581US12404508B2Ketohexokinase (KHK) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Sep 2, 2025·0 cites·29 claims
1679US12473550B2Coagulation factor V (F5) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Nov 18, 2025·0 cites·55 claims
1778US9487797B2Genomic plant sequences and uses thereofBOUKHAROV ANDREY A·Filed 2011·Granted Nov 8, 2016·2 cites·22 claims
1877US2025188456A1High mobility group box-1 (hmgb1) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
1977US2024409929A1Transthyretin (ttr) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
2076US7444243B2Probabilistic method for determining nucleic acid coding featuresMONSANTO TECHNOLOGY LLC·Filed 2004·Granted Oct 28, 2008·2 cites·4 claims
2175US12416006B2Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Sep 16, 2025·0 cites·23 claims
2275US2025027080A1Complement factor b (cfb) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
2375US2024368594A1Huntingtin (htt) irna agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
2474US12365896B2Complement component C3 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Jul 22, 2025·0 cites·52 claims
2573US11649459B2Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseasesALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted May 16, 2023·0 cites·30 claims
2673US2025084418A1Compositions and methods for silencing carbonic anhydrase 2 expressionALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
2772US2024150767A1SUPEROXIDE DISMUTASE 1 (SOD1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SUPEROXIDE DISMUTASE 1- (SOD1-) ASSOCIATED NEURODEGENERATIVE DISEASESALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
2870US12391945B2Coronavirus IRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 19, 2025·0 cites·22 claims
2969US2024209372A1Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
3069US2024318184A1PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
3167US2024182905A1TRANSMEMBRANE PROTEASE, SERINE 6 (TMPRSS6) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
3267US2022411801A1XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
3366US12480125B2Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Nov 25, 2025·0 cites·20 claims
3466US2024240182A1HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
3566US2023392156A1G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
3666US2024124882A1Prion protein (prnp) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
3766US2024392294A1Irna compositions and methods for silencing angiotensinogen (agt)ALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
3865US2024254493A1Compositions and methods for silencing carbonic anhydrase 2 expressionALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
3965US2025034567A1Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
4064US12503699B2Compositions and methods for silencing UGT1a1 gene expressionALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Dec 23, 2025·0 cites·20 claims
4163US2023193268A1APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
4263US2023272382A1COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASESALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
4363US2024018515A1Complement factor b (cfb) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
4462US2023416736A1Mucin 5b (muc5b) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
4562US2024067972A1Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
4662US2025084417A1Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
4762US2023133147A1ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
4861US2024200077A1Stearoyl-coa desaturase 5 (scd5) irna agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
4961US2023416748A1KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
5061US2024301418A1iRNA Compositions and Methods for Silencing Filamin A (FLNA)ALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites

Showing the top 50 of 87 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when James D. Mcininch files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →